Tetrastigma Hemsleyanum Polysaccharide Suppresses Triple-Negative Breast Cancer by Disrupting the

Yini Shang1,2, Wentao Si1,2, Youxue Zhang3

  • 1Fujian Key Laboratory of Tumor Immunotherapy, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Insights

Triple-negative breast cancer cells rely on endoplasmic reticulum (ER) stress. A natural compound, Tetrastigma hemsleyanum polysaccharide (THP), targets the Hippo-YAP/TEAD4-PDIA4 axis to disrupt this ER-stress addiction and block metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Triple-negative breast cancer (TNBC) is aggressive and metastatic.
  • TNBC cells exhibit addiction to chronic endoplasmic reticulum (ER) stress.
  • The unfolded protein response (UPR) sustains the metastatic phenotype in TNBC.

Purpose of the Study:

  • To identify a novel therapeutic strategy targeting ER-stress addiction in TNBC.
  • To investigate the role of the Hippo pathway and TEAD4 in ER stress.
  • To evaluate the efficacy of Tetrastigma hemsleyanum polysaccharide (THP) as a potential treatment.

Main Methods:

  • Investigated the Hippo pathway effector TEAD4 and its regulation of the ER chaperone PDIA4.
  • Utilized THP, a natural polysaccharide, to target the identified axis.
  • Assessed THP's effects on cell signaling, proteostasis, and metastatic potential in vitro and in vivo models.

Main Results:

  • Identified a novel ER-stress addiction axis: TEAD4 upregulates PDIA4.
  • THP activates the Hippo pathway, leading to YAP degradation and reduced TEAD4 activity.
  • THP downregulates PDIA4, disrupts ER proteostasis, and induces lethal ER stress in TNBC cells.
  • THP inhibited migration, invasion, angiogenesis, and metastasis in various models at non-toxic doses.

Conclusions:

  • THP effectively targets the Hippo-YAP/TEAD4-PDIA4 axis in metastatic TNBC.
  • THP disrupts ER-stress addiction, offering a novel therapeutic approach.
  • THP represents a first-in-class, natural-product-based therapeutic for TNBC.